Page last updated: 2024-11-08

3,4-dihydroxyphenylpyruvic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3,4-dihydroxyphenylpyruvic acid: metabolite of L-dopa; RN given refers to unlabeled parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3,4-dihydroxyphenylpyruvic acid : A 2-oxo monocarboxylic acid that is pyruvic acid in which one of the methyl hydrogens is substituted by a 3,4-dihydroxyphenyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID165198
CHEBI ID19891
SCHEMBL ID1331519
MeSH IDM0071737

Synonyms (30)

Synonym
3-(3,4-dihydroxy-phenyl)-2-oxo-propionic acid
4228-66-4
CHEBI:19891
3,4-dihydroxyphenylpyruvic acid
3,4-dihydroxy-alpha-oxobenzenepropanoic acid
3-(3,4-dihydroxyphenyl)-2-oxopropanoic acid
dhppa
C04045
3,4-dihydroxyphenylacetylformic acid
FT-0655694
A801974
109170-71-0
3-[3,4-bis(oxidanyl)phenyl]-2-oxidanylidene-propanoic acid
SCHEMBL1331519
3,4-dihydroxyphenyltyruvic acid
benzenepropanoic acid, 3,4-dihydroxy-alpha-oxo-
AKOS015889780
beta-(3,4-dihydroxylphenyl)pyruvic acid
4,5-dihydroxyphenylacetylformic acid
3-(3,4-dihydroxyphenyl)-2-oxopropanoic acid #
mfcd08460177
3-(3,4-dihydroxyphenyl)-2-oxopropanoicacid
F15598
DS-17541
Q27109260
A872916
DTXSID70962409
benzenepropanoic acid, 3,4-dihydroxy-.alpha.-oxo-
CS-0157104
EN300-1831178

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"The objective of this study was to develop a combined pharmacokinetic model for plasma concentrations of alkylresorcinols and their 2 major metabolites, 3,5-dihydroxybenzoic acid (DHBA) and 3-(3,5-dihydroxyphenyl)-propanoic acid (DHPPA)."( Simultaneous pharmacokinetic modeling of alkylresorcinols and their main metabolites indicates dual absorption mechanisms and enterohepatic elimination in humans.
Hooker, AC; Kamal-Eldin, A; Knudsen, KE; Landberg, R; Lærke, HN; Marklund, M; Strömberg, EA, 2014
)
0.4
" Plasma concentrations of alkylresorcinols and their metabolites depended on absorption and formation, respectively, and the mean ± SEM terminal elimination half-life of alkylresorcinols (1."( Simultaneous pharmacokinetic modeling of alkylresorcinols and their main metabolites indicates dual absorption mechanisms and enterohepatic elimination in humans.
Hooker, AC; Kamal-Eldin, A; Knudsen, KE; Landberg, R; Lærke, HN; Marklund, M; Strömberg, EA, 2014
)
0.4

Bioavailability

ExcerptReferenceRelevance
"Various drugs have been studied in order to improve the bioavailability of L-DOPA."( Effects of 3,4-dihydroxyphenylpyruvic acid and its triacetylated derivative on DOPA decarboxylase.
Lindén, IB; Neuvonen, PJ; Vapaatalo, H, 1982
)
0.65
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
2-oxo monocarboxylic acidAny monocarboxylic acid having a 2-oxo substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (33.33)18.7374
1990's2 (11.11)18.2507
2000's1 (5.56)29.6817
2010's5 (27.78)24.3611
2020's4 (22.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.96 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index4.90 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]